Aflac trails industry rival MetLife as investors weigh slowing premium growth and earnings concerns against the company's reliance on share buybacks to support EPS.
MetLife has demonstrated superior market performance compared to Aflac, with a year-to-date gain of 23.7% and a 19.4% increase over the past 52 weeks. This outperformance highlights a stronger growth trajectory and investor confidence relative to its industry rival.
MetLife has significantly outperformed Aflac, with a 23.7% year-to-date gain compared to Aflac's 6.3%.
Aflac Incorporated faces mounting pressure as shares trade 10% below their 52-week high, trailing the broader insurance sector. Weakened momentum follows a disappointing Q2 earnings miss and an 'Underperform' rating from Wolfe Research, highlighting concerns over slowing growth in the company's critical Japanese market.
Analysts are concerned about slowing operations in Japan, softer premium growth, and the sustainability of earnings growth, which has led to a consensus 'Hold' rating.